Pulmonology — Therapeutic Area Intelligence | Humanexa Signals

ClinicalAugust 6, 2026

Alvelestat (MPH966) Trial for Bronchiolitis Obliterans Syndrome Post-HSCT Initiated

A clinical trial is underway to evaluate the safety and efficacy of alvelestat (MPH966) in patients with bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation.

ClinicalAugust 3, 2026

In Vitro Study on PIP-2 for Immune Cell Blockade in ARDS Patients

An in vitro study will assess the effects of PIP-2 on immune cell activation in ARDS patients.

ClinicalAugust 3, 2026

Study on Echocardiographic PAP Changes for Pulmonary Embolism Risk Stratification

This study aims to evaluate the effectiveness of echocardiographic pulmonary artery pressure changes in predicting pulmonary embolism risk in emergency department patients.

CompetitiveAugust 2, 2026

Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics

Contineum Therapeutics has initiated Phase 2 trial to assess PIPE-791 in patients with Idiopathic Pulmonary Fibrosis.

ClinicalAugust 2, 2026

Study on Transcutaneous CO2 Measurement During Exercise in COPD and Other Conditions

The study aims to validate transcutaneous CO2 measurement against arterial sampling during exercise in various patient groups.

ClinicalAugust 1, 2026

Study Compares Prone Position Techniques to Reduce Pressure Sores in ARDS Patients

A clinical trial is underway to compare two prone position techniques in ICU patients with ARDS to assess their impact on pressure sore occurrence.

ClinicalJuly 29, 2026

Study Protocol for HFNC in Sedated Endoscopy for High-Risk OSA Patients

A multicentre randomized controlled trial is set to evaluate the efficacy of high-flow nasal cannula oxygenation in patients with high-risk obstructive sleep apnea during sedated endoscopy.

ClinicalJuly 28, 2026

RAMBO trial evaluates pulmonary rehabilitation's impact post-pulmonary embolism

The RAMBO trial assesses the efficacy of pulmonary rehabilitation in patients with persistent dyspnea after anticoagulation for pulmonary embolism.

RegulatoryJuly 28, 2026

Aurobindo Pharma's Pirfenidone Receives FDA Approval Status Update

Aurobindo Pharma's application for Pirfenidone (ANDA212597) has received an approval status update from the FDA.

RegulatoryJuly 27, 2026

FDA Grants Approval for Selexipag Application ANDA214055

The FDA has granted approval for the Selexipag application ANDA214055 submitted by RK Pharma.

ClinicalJuly 27, 2026

Trial Comparing FCV and PCV in Moderate to Severe ARDS Initiated

A clinical trial has been initiated to compare flow-controlled ventilation (FCV) and pressure-controlled ventilation (PCV) in ARDS patients.

ClinicalJuly 26, 2026

Study Aims to Identify Blood Biomarkers for Obstructive Sleep Apnea

A clinical trial is underway to identify blood biomarkers that could enhance the diagnosis and monitoring of obstructive sleep apnea (OSA).

ClinicalJuly 22, 2026

Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease

Inhaled 3% hypertonic saline is associated with improved symptoms and microbiological stabilization in patients with antibiotic-naïve NTM-LD.

CompetitiveJuly 21, 2026

Phase 2 Study of LTI-03 in Idiopathic Pulmonary Fibrosis Patients Initiated by Rein Therapeutics

Rein Therapeutics is conducting Phase 2 trial of LTI-03, an inhaled medication for IPF, comparing it to placebo.

ClinicalJuly 16, 2026

Trial on Optimal Oxygen Saturation Levels for Children with Respiratory Distress

A clinical trial is underway to determine the optimal oxygen saturation levels for children with respiratory distress, comparing thresholds of 88% and 92%.

ClinicalJuly 15, 2026

Study on mHealth Smoking Cessation for African Americans with HIV/AIDS Initiated

A study is underway to evaluate an mHealth intervention for smoking cessation among Black individuals with HIV/AIDS.

ClinicalJuly 10, 2026

Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases

A clinical trial is underway to evaluate the efficacy of nerandomilast in patients with lung fibrosis related to systemic autoimmune rheumatic diseases.

ClinicalJuly 10, 2026

Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression

A clinical trial is underway to evaluate the efficacy of nerandomilast in patients with fibrosing interstitial lung disease at risk for progression.

RegulatoryJuly 9, 2026

Nerandomilast (Jascayd) Approved for Idiopathic and Progressive Pulmonary Fibrosis

Nerandomilast has received approval from the MHRA for the treatment of adult patients with idiopathic and progressive pulmonary fibrosis.

ClinicalJuly 8, 2026

United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

The ADVANCE CAPACITY study evaluates ralinepag's impact on exercise capacity in patients with WHO Group 1 pulmonary hypertension.

StrategyJuly 5, 2026

Aurobindo Pharma's Pirfenidone ANDA Submission Receives AP Status

Aurobindo Pharma has submitted ANDA212597 for Pirfenidone, which has received Abbreviated Approval (AP) status.

ClinicalJuly 4, 2026

Study on 19F MRI in Children with Mild Cystic Fibrosis Lung Disease

A study is underway to assess the feasibility of 19F MRI in children with cystic fibrosis and healthy controls.

ClinicalJuly 3, 2026

Phase IIb Trial of Autoantibody Reduction Therapy for Progressive IPF Initiated

A Phase IIb trial is underway to evaluate a multi-component autoantibody reduction therapy for progressive IPF.

ClinicalJuly 2, 2026

Phase 2 Trial of Nintedanib DPI in Idiopathic Pulmonary Fibrosis Initiated by Mannkind Corporation

Mannkind Corporation is conducting Phase 2 trial of inhaled Nintedanib DPI in patients with IPF, focusing on safety and preliminary efficacy.

ClinicalJune 30, 2026

Study on Phenotyped Diffuse Interstitial Lung Disease Launched in France

A new cohort study is being conducted to analyze patients with diffuse interstitial lung disease at French hospital.

ClinicalJune 26, 2026

Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients

A follow-up study is underway to evaluate the long-term tolerance and efficacy of nerandomilast in patients with pulmonary fibrosis.

ClinicalJune 26, 2026

Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children

A new study aims to investigate the impact of air pollution on lung disease severity in Hispanic children with cystic fibrosis.

ClinicalJune 23, 2026

Study on Elexacaftor/Tezacaftor/Ivacaftor's Impact on Cystic Fibrosis Microbiota

A clinical trial is assessing the effects of elexacaftor/tezacaftor/ivacaftor on lung and digestive microbiota in cystic fibrosis patients.

ClinicalJune 23, 2026

Study on Risk Factors for Acute Pulmonary Hypertension Crisis Launched

An observational study has been initiated to assess risk factors and mechanisms of acute pulmonary hypertension crisis.

ClinicalJune 22, 2026

Study Identifies Malignancy Risk Factors for Pulmonary Nodules in Bronchiectasis Patients

The study identifies specific risk factors that differentiate benign from malignant pulmonary nodules in bronchiectasis patients.

ClinicalJune 22, 2026

Trial on Oxygen Saturation Targeting in Preterm Infants with Pulmonary Hypertension

A clinical trial is underway to evaluate the impact of varying oxygen levels on outcomes in preterm infants with pulmonary hypertension.

ClinicalJune 17, 2026

Phase 3 Study of L606 in Patients with PH-ILD Shows Safety and Efficacy Potential

A Phase 3 study is evaluating the safety and efficacy of L606 in patients with pulmonary hypertension due to interstitial lung disease.

ClinicalJune 15, 2026

Phase 3 Trial of Maridebart Cafraglutide in Obstructive Sleep Apnea Patients

A Phase 3 trial is underway to assess maridebart cafraglutide's efficacy and safety in OSA patients not using PAP therapy.

StrategyJune 15, 2026

Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal

Lilly's Zepbound® is highlighted as the first prescription treatment for moderate-to-severe obstructive sleep apnea in adults with obesity.

Companies

Assets

Recent signals(34)